What does it take to be a driver of the biosimilar revolution?

14 December 2018

Given that copycat biologics are a relatively new part of the healthcare landscape, especially in the USA, the blueprint on how to become a successful biosimilars company is yet to established.

What are the optimal discounts to offer on the reference products to deliver savings for healthcare systems while protecting margins? What marketing techniques will ensure widespread take-up in the US market? What do physicians need to be assured of biosimilarity and interchangeability?

All these questions and more are yet to be answered, but the identity of the companies that will answer them is becoming clearer as copies of some of the world’s leading biologics reach more and more patients in the world’s major markets.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK